1ORNBV Orion Corporation

ORION CORPORATION MANAGERS’ TRANSACTIONS 08 JANUARY 2024 at 11.00 EET         

Orion Corporation: Managers’ transactions – Ari Lehtoranta

Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.

Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Ari LehtorantaPosition: Member of the Board/Deputy member Issuer: Orion OyjLEI: 74370029VAHCXDR7B745Notification type: INITIAL NOTIFICATIONReference number: 48709/5/4____________________________________________Transaction date: 2023-04-28Venue: NASDAQ HELSINKI LTD (XHEL)Instrument type: SHAREISIN: FI0009014377Nature of transaction: ACQUISITION Transaction details(1): Volume: 694 Unit price: 43.12 EUR Aggregated transactions (1): Volume: 694 Volume weighted average price: 43.12 EUR

Orion Corporation

Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp://www.orion.fi/enhttp://www.twitter.com/OrionCorpIR

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De Abr 2024 a May 2024

Orion (BIT:1ORNBV)
Gráfica de Acción Histórica
De May 2023 a May 2024